Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | RHEB | Q15382 | 3/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29720357 | 1.00 | GAA (0.49) | GAAHTTARKDM4EALDH1A1 | |
| SCHEMBL7734462 | 0.87 | AR (0.40) | GAAHTTARKDM4EALDH1A1 | |
| SCHEMBL7113015 | 0.86 | EGLN1 (0.39) | GAAHTTARKDM4EALDH1A1 | |
| SCHEMBL7122061 | 0.84 | AR (0.43) | ARKDM4EALDH1A1CACNA1HEGLN1 | |
| SCHEMBL7808969 | 0.83 | GAA (0.46) | GAAHTTARRHEBGRIN2D | |
| SCHEMBL7214338 | 0.79 | KDM4E (0.43) | HTTKDM4EALDH1A1EGLN1MCHR1 | |
| SCHEMBL7209326 | 0.77 | RHEB (0.44) | GAAHTTARKDM4EALDH1A1 | |
| SCHEMBL31265260 | 0.76 | GAA (0.57) | GAAHTTARGLP1RRHEB | |
| SCHEMBL7215070 | 0.76 | GAA (0.49) | GAAHTTARGLP1RRHEB | |
| SCHEMBL27241025 | 0.76 | GAA (0.57) | GAAHTTARGLP1RRHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6307043-B1 | FOR TREATMENT OR PROPHYLAXIS OF HERPES VIRAL INFECTIONS | GLAXO WELLCOME INC. | 2001-10-23 | — | — | US | claimed |
| US-20010003744-A1 | Therapeutic compounds | CHAMBERLAIN STANLEY DAWES (US) | 2001-06-14 | — | — | US | claimed |
| WO-1996001833-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-25 | — | — | WO | claimed |
| US-20260108495-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEROF, AND INTERMEDIATES THERETO | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20260097018-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-04-09 | — | — | US | disclosed |
| US-20260076945-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-03-19 | — | — | US | disclosed |
| US-20260076946-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-03-19 | — | — | US | disclosed |
| US-12527771-B2 | Viral inhibitors, the synthesis thereof, and intermediates thereto | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20250332146-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TAKEDA PHARMACEUTICALS CO (JP) | 2025-10-30 | — | — | US | disclosed |
| US-12377078-B2 | Viral inhibitors, the synthesis thereof, and intermediates thereto | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| US-12295941-B2 | Viral inhibitors, the synthesis thereof, and intermediates thereto | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-05-13 | — | — | US | disclosed |
| EP-0769017-B1 | THERAPEUTIC COMPOUNDS | WELLCOME FOUND (GB) | 2000-05-24 | — | — | EP | disclosed |
| EP-0970100-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-01-12 | — | — | EP | disclosed |
| US-5998605-A | Antiviral benzimidazole nucleoside analogues and method for their preparation | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5998398-A | HERPES VIRUS | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0886635-A1 | 2-AMINO-5,6-DICHLOROBENZIMIDAZOLE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | GLAXO GROUP LIMITED (GB) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998035977-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
| WO-1997025316-A1 | 2-AMINO-5,6-DICHLOROBENZIMIDAZOLE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | GLAXO GROUP LIMITED (GB) | 1997-07-17 | — | — | WO | disclosed |
| EP-0769017-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001833-A1 | THERAPEUTIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377078-B2 | Viral inhibitors, the synthesis thereof, and intermediates thereto | TYMS, TYMP, DUT | GAA 489/4885HTT 4213/4885AR 3962/4885 |
| US-20260076946-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TPMT, MPST, PCMT1 | GAA 2561/4885HTT 2378/4885AR 4194/4885 |
| US-12295941-B2 | Viral inhibitors, the synthesis thereof, and intermediates thereto | TYMS, TYMP, DUT | GAA 489/4885HTT 4213/4885AR 3962/4885 |
| US-12527771-B2 | Viral inhibitors, the synthesis thereof, and intermediates thereto | IRF3, RPL12, MCM4 | GAA 1589/4885HTT 4624/4885AR 3722/4885 |
| US-20260097018-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | TPMT, PCMT1, RPL7 | GAA 2824/4885HTT 2995/4885AR 4448/4885 |
| US-20250332146-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | MAVS, SARS1, POLRMT | GAA 164/4885HTT 3649/4885AR 3801/4885 |
| US-20260076945-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | PCMT1, MPST, TPMT | GAA 2387/4885HTT 2561/4885AR 4671/4885 |
| US-20010003744-A1 | Therapeutic compounds | ZC3HAV1, HAVCR2, EIF2AK2 | GAA 98/4885HTT 2409/4885AR 4743/4885 |
| US-20260108495-A1 | VIRAL INHIBITORS, THE SYNTHESIS THEROF, AND INTERMEDIATES THERETO | HYOU1, CYP2F1, HAVCR2 | GAA 524/4885HTT 1729/4885AR 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.